Related Experiment Video
Updated: May 17, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53
Ido Goldstein1, Noa Rivlin, Or-yam Shoshana
1The Department of Molecular Cell Biology, the Weizmann Institute of Science, Rehovot, 76100 Israel. Ido.goldshtein@weizmann.ac.il
Abstract:
Cytochrome P450 (P450) enzymes are abundantly expressed in the human liver where they hydroxylate organic substrates. In a microarray screen performed in human liver cells, we found a group of eleven P450 genes whose expression was induced by p53 (CYP3A4, CYP3A43, CYP3A5, CYP3A7, CYP4F2, CYP4F3, CYP4F11, CYP4F12, CYP19A1, CYP21A2 and CYP24A1). The mode of regulation of four representative genes (CYP3A4, CYP3A7, CYP4F2 and CYP4F3) was further characterized. The genes were induced in a p53-dependent manner in HepG2 and Huh6 cells (both are cancer-derived human liver cells) and in primary liver cells isolated from human donors. Furthermore, p53 was found to bind to p53-responsive elements in the genes' DNA-regulatory regions and to enhance their transcription in a reporter gene assay. Importantly, when p53 was activated following the administration of either of three different anticancer chemotherapeutic agents (cisplatin, etoposide or doxorubicin), it was able to induce CYP3A genes, which are the main factors in systemic clearance of these agents. Finally, the p53-dependent induction of P450 genes following either Nutlin or chemotherapy treatment led to enhanced P450 enzymatic activity. Thus, in addition to the well-established role of p53 at the tumor site, our data unravels a novel function of hepatic p53 in inducing P450 enzymes and position p53 as a major factor in the hepatic response to xenobiotic and metabolic signals. Importantly, this study reveals a novel pathway for the induction of CYP3As by their substrates through p53, warranting the need for careful consideration when designing systemically administered chemotherapeutic regimens.
Insights
The tumor suppressor p53 (a protein) activates liver P450 enzymes, impacting drug metabolism. This discovery reveals a new role for p53 in how the liver processes substances, crucial for chemotherapy design.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Cytochrome P450 (P450) enzymes are crucial for metabolizing organic substrates, primarily in the liver.
- The p53 protein is a well-known tumor suppressor involved in cellular responses to DNA damage.
Purpose of the Study:
- To investigate the role of p53 in regulating the expression of P450 genes in human liver cells.
- To characterize the mechanism of p53-mediated induction of specific P450 genes.
Main Methods:
- Microarray screening of P450 gene expression in human liver cells.
- p53-dependent gene induction studies in liver cell lines and primary human hepatocytes.
- Analysis of p53 binding to DNA regulatory regions and reporter gene assays.
- Assessment of P450 enzyme activity following p53 activation by chemotherapeutic agents.
Main Results:
- Eleven P450 genes were found to be induced by p53 in human liver cells.
- p53 directly binds to regulatory elements and enhances transcription of P450 genes.
- Activation of p53 by chemotherapy (cisplatin, etoposide, doxorubicin) induced CYP3A genes, enhancing P450 activity.
Conclusions:
- Hepatic p53 plays a novel role in inducing P450 enzymes, influencing the response to xenobiotics and metabolic signals.
- This p53-mediated induction of CYP3A enzymes by their substrates necessitates careful consideration in chemotherapy regimen design.
Related Concept Videos
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

